HBV reactivation during the treatment of non-Hodgkin lymphoma and management strategies
X Cao, Y Wang, P Li, W Huang, X Lu, H Lu - Frontiers in Oncology, 2021 - frontiersin.org
Hepatitis B virus reactivation (HBV-R), which can lead to HBV-related morbidity and
mortality, is a common and well-known complication that occurs during the treatment of non …
mortality, is a common and well-known complication that occurs during the treatment of non …
[HTML][HTML] Incidence rate and treatment strategy of immune checkpoint inhibitor mediated hepatotoxicity: A systematic review
K Miao, L Zhang - Cancer Pathogenesis and Therapy, 2023 - Elsevier
Background A hepatic adverse event (HAE) is defined as a liver injury that occurs following
immune checkpoint inhibitor (ICI) administration in oncology Patients. Immune-mediated …
immune checkpoint inhibitor (ICI) administration in oncology Patients. Immune-mediated …
Pembrolizumab-induced acute exacerbation of hepatitis D
A Fichtl, A Beck, T Seufferlein… - Zeitschrift für …, 2023 - thieme-connect.com
A 55-year-old man was treated with combined immunochemotherapy (pembrolizumab,
carboplatin and pemetrexed) because of non-small cell lung cancer (NSCLC). In addition …
carboplatin and pemetrexed) because of non-small cell lung cancer (NSCLC). In addition …
Hepatitis aguda grave inmunomediada por pembrolizumab: a propósito de un caso
C Stehli, F Cabrera, P Lucero… - … Investigación Aplicada a …, 2023 - methodo.ucc.edu.ar
Hepatitis aguda grave inmunomediada por pembrolizumab: a propósito de un caso Acute
severe immune mediated hepatitis due to pe Page 1 Revista Methodo: Investigación Aplicada …
severe immune mediated hepatitis due to pe Page 1 Revista Methodo: Investigación Aplicada …